Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesAmortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Avalon GloboCare (ALBT) Research & Development (2018 - 2023)

Avalon GloboCare filings provide 6 years of Research & Development readings, the most recent being -$542.0 for Q4 2023.

  • On a quarterly basis, Research & Development fell 100.29% to -$542.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $109618.0, a 85.01% decrease, with the full-year FY2023 number at $109618.0, down 85.01% from a year prior.
  • Research & Development hit -$542.0 in Q4 2023 for Avalon GloboCare, down from $17810.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $949711.0 in Q2 2019 to a low of -$554730.0 in Q4 2021.
  • Median Research & Development over the past 5 years was $208920.0 (2020), compared with a mean of $190947.0.
  • Biggest five-year swings in Research & Development: skyrocketed 361006.84% in 2019 and later plummeted 365.52% in 2021.
  • Avalon GloboCare's Research & Development stood at $414559.0 in 2019, then plummeted by 49.6% to $208920.0 in 2020, then plummeted by 365.52% to -$554730.0 in 2021, then soared by 134.21% to $189762.0 in 2022, then tumbled by 100.29% to -$542.0 in 2023.
  • The last three reported values for Research & Development were -$542.0 (Q4 2023), $17810.0 (Q2 2023), and $92350.0 (Q1 2023) per Business Quant data.